Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the Progression-free survival (PFS) in subjects receiving BMS-690514 relative to erlotinib.
Critère d'inclusion
- Progressive or recurrent non-small cell lung cancer (NSCLC) after treatment with one to two lines of cytotoxic chemotherapy cáncer de pulmón no microcítico progresivo o recurrente tras tratamiento con una o dos lineas de quimioterapia